Related Experiment Video

Updated: Apr 6, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Effect of Previous Exposure to HBV on Liver Histology and Treatment Response in CHC Patients

Haider Ali Khan1, Muhammad Umar2, Hamama-tul-Bushra2

  • 1Center for Liver and Digestive Diseases (CLD),Holy Family Hospital, Rawalpindi.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|July 26, 2015
PubMed

Insights

Previous hepatitis B virus (HBV) infection does not adversely affect liver histology or treatment outcomes in chronic hepatitis C (CHC) patients. This study found no significant impact of prior HBV exposure on liver health or response to CHC treatment.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Background:

  • Chronic hepatitis C (CHC) is a significant global health concern.
  • Coinfection with hepatitis B virus (HBV) is common in CHC patients.
  • The impact of prior HBV exposure on CHC progression and treatment is not fully understood.

Purpose of the Study:

  • To investigate the influence of previous HBV exposure on liver histology in CHC patients.
  • To analyze the effect of prior HBV infection on treatment outcomes for CHC.
  • To compare liver histology and treatment responses between CHC patients with and without serological evidence of past HBV infection.

Main Methods:

  • A case-control study was conducted retrospectively.
  • Medical records of 592 CHC patients were analyzed from January 2011 to December 2012.
  • Patients were categorized into cases (anti-HBc positive) and controls (anti-HBc negative), with comparisons of virological and treatment responses and histological changes.

Main Results:

  • Of 592 CHC patients, 42.9% showed evidence of previous HBV infection (anti-HBc positive).
  • No significant differences in end-treatment response (ETR) or sustained virological response (SVR) were observed between groups.
  • In patients with available liver biopsy data, those with prior HBV infection were more likely to respond in the absence of fibrosis (p=0.001), while controls responded better in the presence of fibrosis (p=0.001).
  • Anti-HBc positivity did not significantly affect inflammation grades or treatment response (p=0.14).

Conclusions:

  • A substantial proportion of CHC patients in Pakistan exhibit markers of previous HBV infection.
  • Previous HBV infection, indicated by anti-HBc positivity, does not appear to negatively impact liver histology or treatment outcomes in CHC patients.
  • These findings suggest that prior HBV exposure may not be a significant confounding factor in managing CHC.
Abstract

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.3K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
42
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
337
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
309